Zenas Biopharma licenses three autoimmune candidates from InnoCare
PositiveFinancial Markets

Zenas Biopharma has successfully licensed three promising autoimmune candidates from InnoCare, marking a significant step forward in their development pipeline. This collaboration not only enhances Zenas's portfolio but also underscores the growing importance of innovative treatments in the autoimmune space. The partnership is expected to accelerate research and bring new therapies to patients in need, highlighting the potential for improved health outcomes.
— Curated by the World Pulse Now AI Editorial System